lifestyle.gamezon.net

Author: Edison Oncology Holding Corp.

Edison Oncology Presents New Preclinical Data on EO1001 and EO4426 Highlighting Differentiated Targeting of Cancer Resistance Pathways at AACR 2026

April 23, 2026
Edison Oncology Completes Target Enrollment in Phase 1/2a Orotecan(TM) Clinical Trial

March 20, 2026
Edison Oncology to Present Two Posters at the 2026 AACR Annual Meeting

March 18, 2026